pay for delay

  • June 5, 2015  

    The Federal Trade Commission’s recent $1.2 billion settlement over the drug Provigil has brought so-called “pay for delay” deals for generic drugs back into the spotlight. Opponents say these deals delay generic medications to market, costing consumers billions. But drug companies say that the deals help get generics to market by avoiding lengthy patent litigation. NewsHour’s Megan Thompson reports. Continue reading

  • June 28, 2014  

    Are generic drugs being delayed to market by so-called “pay for delay” deals between drug companies? The deals happen after generic drug companies challenge the patents on brand-name drugs. The settlements include a date that the generic drug can enter the market, and in some cases, a payment from brand company to the generic company. Continue reading